Malaria Lab Research

Despite the tremendous progress made in combating malaria, one child still dies from the disease every two minutes. Novartis is committed to contributing to the WHO’s target of reducing malaria-related child mortality by at least 90% in 2030.

Novartis has been committed to the fight against malaria for more than two decades. In 1999 we launched the first fixed-dose Artemisinin-based combination therapy (ACT) and in 2009 the first dispersible pediatric ACT developed in partnership with Medicines for Malaria Venture (MMV).

Over the past 20 years, together with our partners, we have delivered more than 1 billion treatments, including over 430 million pediatric treatments to malaria-endemic countries.

Read more about the Malaria Initiative